Notes

Humoral response was assessed with Spike-specific IgG antibody response (S-IgG) and neutralizing antibodies (NtAb)
Specific T cell response was assessed by enzyme linked immunosorbent spot (ELISpot). RESULTS: Of 56 included patients with GCA, 44 were eligible after exclusion of previous evidence of COVID-19 and incomplete follow-up. A significant proportion of patients with GCA (91%) demonstrated antibody (S-IgG) response, but this was significantly lower than HCs (100%); P < 0.0001. Neutralizing activity was not detected in 16% of patients with GCA. Antibody titres (S-IgG and NtAb) were significantly lower compared with HCs.

Humoral response (S-IgG and NtAb) was significantly hampered by treatment with MTX. Cellular response was lacking in 30% of patients with GCA (vs 0% in HCs; P < 0.0001). Cellular response was significantly influenced by the levels of baseline peripheral T-lymphocytes and by glucocorticoid treatment. Treatment with tocilizumab did not affect any level of the immune response elicited by vaccination. CONCLUSIONS: Although patients with GCA apparently achieve a robust antibody seroconversion, there is a significant impairment of the neutralizing activity. MTX significantly reduced all levels of the humoral response.

Up to one-third of patients do not develop a cellular immune protection in response to British Society for Rheumatology. All rights reserved. For permissions, please previously uninfected calves. However, cattle develop a strong protective immune response upon exposure to the parasite. In order to evaluate whether soluble parasite antigens could induce protective immunity, a soluble fraction was obtained from disrupted adult worms, and this fraction was used to vaccinate calves. Mechanistic Studies of 6-butyl-n-hydroxynaphthimide trifluoromethanesulfonic acid Reactions involved two immunizations. 6-butyl-n-hydroxynaphthimide trifluoromethanesulfonic acid in Electrophilic Aromatic Substitution was administered intramuscularly with complete Freund's adjuvant, the second was given intraperitoneally with antigen plus alum.

This immunization reduced the number of worms developing from a subsequent challenge infection by 85% and also reduced clinical signs associated with infection with adult worms. However, vaccination resulted in decreased weight gains during the larval phase of the infection. Analysis of the immune response generated in the vaccinated calves indicated that protection from infection was significantly correlated with the levels of: (1) circulating parasite-specific IgG2 antibody; (2) cellular immune reactivity as determined in a conventional parasite-specific lymphocyte proliferation assay. Serum anti-O. radiatum IgG2 antibodies from vaccinated calves were used in immunoblots to identify the major immunogens. There were five major immunogens with molecular weights ranging from 70 to 150 kDa. Fractions separated by high-pressure liquid chromatography contained immunogens that were used to immunize calves.

Vaccination with these fractions was found to impart the same level of protective immunity and induced similar IgG2 antibody and cellular immune responses as the crude whole worm extract even with 100-fold less protein.expressing Toxoplasma gondii cyst wall protein.micronemal antigens, or other subcellular compartment proteins have shown limited vaccine efficacies. T. gondii cyst wall protein (CST1) as a cyst persistence factor is critical for cyst wall integrity and bradyzoite persistence. Here, we generated influenza virus-like particles (VLPs) expressing the T. gondii CST1 and evaluated the mucosal as well as systemic immunities induced by VLPs.

Intranasal immunization with the VLPs induced parasite-specific IgG and IgA antibody responses in sera and intestines. VLP immunization showed higher levels of germinal center B cell response and antibody-secreting cell (ASC) response upon challenge infection, indicating memory B cell response was induced. VLP-immunized mice showed a significant reduction of cyst counts and lower levels of pro-inflammatory cytokines (IFN-γ, IL-6) production in the brain upon T. gondii ME49 challenge infection compared to unimmunized control. Thus, VLP immunization protected mice from the lethal dose challenge infection with T. gondii ME49 and did not incur bodyweight loss. These results indicated that T.

gondii CST1 containing VLPs can induce mucosal and systemic immunity and also suggest its developmental potential as an effective vaccine candidate against T.
Homepage: http://allinno.com/news/166.html